HF Sinclair Corporation Common Stock vs DexCom, Inc. — how do they compare? HF Sinclair Corporation Common Stock trades at $121.83 (market cap $21.46B), while DexCom, Inc. trades at $84.91 (market cap $31.86B). The key difference: DexCom, Inc. is the larger of the two by market cap, and HF Sinclair Corporation Common Stock pays a 1.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HF Sinclair Corporation Common Stock for 0 Days and DexCom, Inc. for 62 Days on average.
| DINO | DXCM | |
|---|---|---|
Market Cap | $21.46B | $31.86B |
Volume | 2,430,580 | 3,607,070 |
Sector | Energy | Health |
52-Week High | $120.72 | $92.34 |
52-Week Low | $45.88 | $54.84 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $22.44B | $31.32B |
Dividend Yield | 1.74% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HF Sinclair refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics and renewable fuels businesses.
Read more on DINO →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →